SequelSEC

Boundless Bio, Inc. BOLD

Pharmaceutical Preparations · CIK 0001782303 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$63.55M
Fiscal year ended 2025-12-31
Free cash flow
-$47.21M
Fiscal year ended 2025-12-31

Boundless Bio, Inc. (BOLD) reported net income of -$58.20M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Boundless Bio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Boundless Bio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$63.55M-$73.27M-$54.80M
Net income-$58.20M-$65.36M-$49.43M
Research & development$44.84M$55.27M$42.64M
Weighted-average diluted sharesshares 22.36Mshares 16.98Mshares 1.22M
Pretax incomeUnavailableUnavailableUnavailable
Income tax expense$0$0Unavailable
Diluted EPS$-2.60$-3.85$-40.65
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$18.71M$18.00M$12.16M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Boundless Bio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$17.87M$26.59M$23.71M
Total assets$157.06M$206.41M$129.89M
Current assets$109.61M$154.39M$124.20M
Total liabilities$58.40M$55.77M$9.36M
Current liabilities$12.54M$8.14M$9.36M
Total equity incl. NCI$98.65M$150.64M-$127.08M
Temporary (mezzanine) equityUnavailable$0$247.62M
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$1.49M$1.27M$2.22M

Cash flow

Boundless Bio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$46.66M-$60.84M-$46.86M
Capital expenditures$546.00K$2.54M$633.00K
Investing cash flow$37.80M-$26.10M-$38.26M
Financing cash flow$141.00K$89.82M$97.90M
Net change in cash-$8.72M$2.88M$12.78M
Stock-based compensation$6.12M$7.52M$3.34M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortization$1.25M$1.09M$957.00K

Derived

Boundless Bio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$47.21M-$63.38M-$47.49M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio8.74x18.98x13.27x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BOLD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.